

Empowering Progress: Impactful Innovations in HIV Prevention in Africa

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

In the battle against HIV/AIDS, Africa has been a pivotal battleground, grappling with a disproportionate burden of the epidemic. This review delves into the landscape of HIV prevention in Africa, focusing on innovative strategies that have catalyzed progress and empowered communities in the fight against the virus. Behavioral interventions, including community-based education initiatives and technology-driven campaigns, have been instrumental in raising awareness and promoting safer sexual practices. Biomedical innovations such as pre-exposure prophylaxis (PrEP), antiretroviral therapy (ART) as prevention, and voluntary medical male circumcision (VMMC) have revolutionized prevention efforts, while implementation science research has optimized their delivery. Structural reforms and policy innovations have created an enabling environment for HIV prevention, with health system strengthening and policy frameworks facilitating the scale-up of evidence-based interventions. Community empowerment lies at the heart of successful HIV prevention programs in Africa, with community-led initiatives and partnerships driving positive change. By harnessing the power of innovation, collaboration, and community engagement, Africa is making significant strides towards ending the HIV epidemic. This review underscores the importance of building on impactful innovations to sustain progress and achieve the ambitious goal of an AIDS-free generation in Africa.

Keywords: *HIV prevention, Africa, innovations, impact, progress*

Introduction

Citation: Obeagu EI. Empowering Progress: Impactful Innovations in HIV Prevention in Africa. *Elite Journal of Public Health*, 2024; 2 (3): 63-77

The HIV/AIDS epidemic remains a significant public health challenge, particularly in Africa, where the burden of the disease is most pronounced. Despite substantial progress in HIV prevention and treatment, Africa continues to bear a disproportionate share of the global HIV burden, with millions of new infections and deaths reported annually. However, amidst this daunting challenge, there have been notable advancements in HIV prevention strategies, marked by innovative approaches and impactful interventions aimed at curbing transmission and reducing new infections across the continent. Over the past few decades, Africa has witnessed a dynamic evolution in HIV prevention efforts, driven by a combination of scientific advancements, policy reforms, and community engagement initiatives. Behavioral interventions have played a pivotal role in promoting safer sexual practices, raising awareness, and reducing stigma surrounding HIV/AIDS. Concurrently, biomedical innovations have revolutionized prevention strategies, offering new avenues for protection, such as pre-exposure prophylaxis (PrEP), antiretroviral therapy (ART) as prevention, and voluntary medical male circumcision (VMMC), among others.¹⁻²²

Structural reforms and policy innovations have also been instrumental in creating an enabling environment for effective HIV prevention efforts in Africa. Health system strengthening initiatives, including task-shifting and decentralized service delivery, have improved access to prevention, treatment, and care services, while policy frameworks and national HIV/AIDS strategic plans have provided a roadmap for action and resource mobilization. Moreover, community empowerment and participation have emerged as cornerstones of successful HIV prevention programs, ensuring that interventions are contextually relevant, culturally sensitive, and sustainable. Despite these advancements, significant challenges persist in the realm of HIV prevention in Africa. Structural barriers, including poverty, gender inequality, and stigma, continue to impede access to prevention services, particularly among marginalized populations. Additionally, the emergence of new challenges, such as the COVID-19 pandemic, has further strained HIV prevention efforts, highlighting the need for innovative solutions and adaptive strategies to address evolving needs and priorities. In this context, this review aims to explore the landscape of HIV prevention in Africa, highlighting impactful innovations and promising approaches that have empowered progress in the fight against HIV/AIDS on the continent.²³⁻⁴³

Innovations in Behavioral Interventions

Behavioral interventions have long been recognized as essential components of comprehensive HIV prevention strategies, aiming to address underlying risk factors, promote safer sexual practices, and foster behavior change among diverse populations. In Africa, innovative approaches have emerged to enhance the effectiveness and reach of behavioral interventions, adapting to the unique socio-cultural contexts and epidemiological profiles prevalent across the continent. Community-Based Education Programs: Community-based education programs have been instrumental in raising awareness about HIV/AIDS, promoting risk reduction strategies, and dispelling myths and misconceptions surrounding the virus. These programs often involve grassroots initiatives led by community health workers, peer educators, and local leaders who are culturally competent and trusted within their communities. By engaging directly with community members through workshops, outreach events, and peer support groups, these programs facilitate

Citation: Obeagu EI. Empowering Progress: Impactful Innovations in HIV Prevention in Africa. *Elite Journal of Public Health*, 2024; 2 (3): 63-77

open dialogue, empower individuals to make informed decisions about their sexual health, and reduce stigma associated with HIV/AIDS. **Peer-Led Initiatives:** Peer-led interventions harness the power of peer networks to disseminate information, provide support, and promote behavior change among at-risk populations. Peer educators, drawn from the same communities as their peers, are uniquely positioned to deliver targeted messages in a relatable and non-judgmental manner. These interventions often leverage peer influence and social networks to promote safer sexual practices, encourage HIV testing and counseling, and facilitate access to prevention services. By fostering a sense of camaraderie and solidarity, peer-led initiatives create supportive environments that empower individuals to adopt healthy behaviors and reduce their risk of HIV infection.⁴⁴⁻⁶⁵

Culturally Tailored Interventions: Cultural factors play a significant role in shaping attitudes, beliefs, and behaviors related to HIV/AIDS in African communities. Culturally tailored interventions seek to align HIV prevention messages and strategies with local customs, traditions, and socio-cultural norms, making them more relevant and acceptable to target populations. This may involve incorporating traditional storytelling, music, dance, and drama into prevention campaigns, as well as engaging community elders, religious leaders, and traditional healers as advocates and allies in the fight against HIV/AIDS. By respecting cultural sensitivities and preferences, these interventions enhance community engagement and uptake of HIV prevention services. **Technology-Driven Campaigns:** The widespread use of mobile phones and digital technology has provided new opportunities for reaching populations with HIV prevention messages and services. Technology-driven campaigns leverage mobile health (mHealth) platforms, social media, and interactive messaging apps to disseminate information, facilitate behavior change communication, and provide support remotely. These interventions are particularly effective among younger populations who are digital natives and are more likely to engage with technology-based interventions. By harnessing the power of technology, these campaigns extend the reach of HIV prevention efforts, overcome barriers of distance and accessibility, and empower individuals to take control of their sexual health.⁶⁶⁻⁸⁵

Biomedical Innovations

Biomedical innovations have revolutionized HIV prevention strategies in Africa, offering new avenues for protection and significantly impacting the trajectory of the epidemic. These innovations leverage scientific advancements to provide effective and accessible tools for reducing HIV transmission and improving public health outcomes across the continent. **Pre-exposure Prophylaxis (PrEP):** Pre-exposure prophylaxis (PrEP) represents a groundbreaking biomedical innovation that has transformed HIV prevention efforts in Africa. PrEP involves the use of antiretroviral medications by HIV-negative individuals to prevent HIV acquisition during sexual activity or injection drug use. Clinical trials and real-world studies have demonstrated the effectiveness of PrEP in reducing the risk of HIV transmission by over 90% when taken consistently. In Africa, PrEP implementation programs have been scaled up in diverse settings, including clinics, community health centers, and key population networks, to reach individuals at high risk of HIV infection. **Antiretroviral Therapy (ART) as Prevention:** Antiretroviral therapy (ART) not only serves as a life-saving treatment for individuals living with HIV but also has a preventive effect in reducing HIV transmission. The concept of "treatment as prevention" relies

Citation: Obeagu EI. Empowering Progress: Impactful Innovations in HIV Prevention in Africa. *Elite Journal of Public Health*, 2024; 2 (3): 63-77

on the suppression of HIV viral load through early initiation and adherence to ART, which significantly reduces the risk of onward transmission to uninfected partners. In Africa, expanded access to ART through national treatment programs has not only improved health outcomes for people living with HIV but has also contributed to reductions in HIV incidence at the population level.⁸⁶⁻⁹¹

Voluntary Medical Male Circumcision (VMMC): Voluntary medical male circumcision (VMMC) has emerged as a cost-effective biomedical intervention for reducing the risk of heterosexual HIV transmission among men.⁹² Male circumcision reduces the risk of HIV acquisition by removing the foreskin, which is highly susceptible to HIV infection. Numerous studies have demonstrated the efficacy of VMMC in reducing HIV incidence, prompting the scale-up of VMMC programs across Africa. These programs integrate VMMC services with HIV testing, counseling, and other preventive interventions, making them accessible to men and adolescents in both clinical and community settings. **HIV Testing Technologies:** Innovations in HIV testing technologies have expanded access to HIV diagnosis and facilitated early identification of HIV infection. Rapid diagnostic tests (RDTs), point-of-care (POC) tests, and self-testing kits offer convenient and confidential options for HIV testing, particularly among hard-to-reach populations and those reluctant to access traditional testing services. By decentralizing testing services and promoting community-based testing initiatives, these innovations have increased HIV testing coverage and facilitated timely linkage to care and treatment services for those diagnosed with HIV. **Integration of Biomedical Interventions:** A key innovation in HIV prevention in Africa is the integration of biomedical interventions within a comprehensive prevention package, combining behavioral, biomedical, and structural approaches to maximize impact. Integrated HIV prevention programs leverage synergies between different interventions, such as PrEP, ART, VMMC, condom promotion, and harm reduction services, to address the diverse needs of populations at risk of HIV infection. By adopting a combination prevention approach, these programs offer tailored and holistic solutions that are responsive to the evolving dynamics of the HIV epidemic in Africa.

Structural and Policy Innovations

Structural and policy innovations have been instrumental in creating an enabling environment for effective HIV prevention efforts in Africa.⁹³ These innovations address systemic barriers and institutional gaps, facilitating the implementation and scale-up of evidence-based interventions to reduce HIV transmission and improve public health outcomes across the continent. **Health Systems Strengthening:** One of the key structural innovations in HIV prevention in Africa is health systems strengthening. This involves strengthening healthcare infrastructure, workforce capacity, and service delivery systems to ensure equitable access to HIV prevention, treatment, and care services. Health systems strengthening initiatives often include task-shifting strategies, where non-physician healthcare workers are trained and empowered to deliver HIV prevention and treatment services, particularly in underserved and resource-limited settings. Additionally, decentralization of HIV services, integration of HIV services into primary healthcare settings, and adoption of differentiated service delivery models have improved access to prevention interventions and optimized the utilization of limited resources. **Policy Frameworks and National Strategies:** Policy innovations have played a critical role in guiding and coordinating HIV prevention efforts at the

Citation: Obeagu EI. Empowering Progress: Impactful Innovations in HIV Prevention in Africa. *Elite Journal of Public Health*, 2024; 2 (3): 63-77

national and regional levels in Africa. National HIV/AIDS strategic plans provide a comprehensive framework for addressing the HIV epidemic, outlining priority interventions, targets, and resource allocation strategies. These strategic plans are often developed through a participatory process involving government agencies, civil society organizations, development partners, and affected communities. Policy frameworks also encompass legislation and regulations that promote human rights, gender equality, and access to healthcare services for key populations, such as men who have sex with men (MSM), sex workers, and people who inject drugs (PWID).

Resource Mobilization and Financing Mechanisms: Innovative financing mechanisms and resource mobilization strategies are essential for sustaining HIV prevention efforts in Africa.⁹⁴ The establishment of dedicated funding streams, such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), has significantly increased financial resources for HIV prevention and treatment programs in low- and middle-income countries. In addition to external funding, domestic resource mobilization through taxation, health insurance schemes, and public-private partnerships has emerged as a sustainable approach to financing HIV programs. Furthermore, innovative financing mechanisms, such as social impact bonds, results-based financing, and pooled procurement, optimize the efficiency and effectiveness of resource utilization, ensuring that investments yield maximum impact in terms of HIV prevention outcomes. **Monitoring and Evaluation Systems:** Robust monitoring and evaluation (M&E) systems are essential for tracking progress, measuring impact, and informing evidence-based decision-making in HIV prevention programs. Innovations in M&E encompass the development and implementation of standardized indicators, data collection tools, and reporting frameworks to monitor the coverage, quality, and effectiveness of HIV prevention interventions. These systems facilitate real-time data analysis, performance monitoring, and course corrections, enabling program managers to identify gaps, allocate resources strategically, and scale up successful interventions. Additionally, innovations in data management, including electronic medical records, health information systems, and geographic information systems (GIS), enhance data accuracy, interoperability, and accessibility, strengthening the overall accountability and transparency of HIV prevention efforts. **Community Engagement and Participation:** Community engagement and participation are central to the success of HIV prevention programs in Africa, ensuring that interventions are culturally appropriate, responsive to community needs, and sustainable in the long term. Innovative approaches to community engagement include the establishment of community advisory boards, involvement of community health workers and peer educators, and engagement of affected populations in program design, implementation, and monitoring. Community-led advocacy initiatives, social mobilization campaigns, and participatory research methodologies empower communities to take ownership of their health, demand accountability from policymakers, and drive positive change in HIV prevention efforts.

Community Empowerment and Participation

Community empowerment and participation are fundamental pillars of successful HIV prevention efforts in Africa, fostering ownership, accountability, and sustainability within affected communities.⁹⁵ By actively engaging communities in the design, implementation, and evaluation of prevention programs, innovative approaches empower individuals to take control of their health,

Citation: Obeagu EI. Empowering Progress: Impactful Innovations in HIV Prevention in Africa. *Elite Journal of Public Health*, 2024; 2 (3): 63-77

address underlying social determinants of HIV transmission, and drive positive change at the grassroots level. **Peer-Led Initiatives:** Peer-led initiatives harness the strength of community networks and lived experiences to deliver targeted HIV prevention interventions. Peer educators, drawn from the same communities as their peers, serve as trusted sources of information, support, and advocacy, facilitating open dialogue and behavior change among at-risk populations. These initiatives often employ peer outreach, peer education sessions, and peer support groups to disseminate information about HIV prevention, promote risk reduction strategies, and encourage uptake of prevention services. By leveraging peer influence and solidarity, these initiatives foster a sense of belonging and empowerment, enabling individuals to make informed decisions about their sexual health and well-being. **Community-Led Advocacy:** Community-led advocacy plays a crucial role in advancing HIV prevention agendas, advocating for policy reforms, and mobilizing resources to address the needs of affected communities. Grassroots organizations, civil society groups, and networks of people living with HIV/AIDS (PLWHA) serve as powerful advocates for the rights, dignity, and well-being of marginalized populations, including key populations such as men who have sex with men (MSM), sex workers, and people who inject drugs (PWID). These advocacy efforts often focus on challenging stigma and discrimination, promoting human rights, and advocating for increased access to HIV prevention services, including HIV testing, condoms, and harm reduction programs.

Engagement of Key Populations: Meaningful engagement of key populations is essential for tailoring HIV prevention interventions to the specific needs and contexts of diverse communities.⁹⁶ Key populations, including MSM, sex workers, transgender individuals, and PWID, face heightened vulnerabilities to HIV infection due to stigma, discrimination, and legal barriers. Innovative approaches to community empowerment involve the establishment of community-led organizations, peer support networks, and advocacy platforms that provide a safe space for key populations to access information, services, and support. By centering the voices and experiences of key populations in HIV prevention efforts, these initiatives promote inclusivity, reduce barriers to care, and empower marginalized communities to advocate for their rights and well-being. **Capacity Building and Leadership Development:** Community empowerment extends beyond the delivery of HIV prevention services to encompass capacity building and leadership development initiatives that foster resilience, self-reliance, and sustainability within communities. Training programs, workshops, and mentorship opportunities empower community members to develop essential skills, build confidence, and take on leadership roles in shaping HIV prevention agendas. By investing in the capacity of local leaders, activists, and organizations, communities become better equipped to respond to the evolving challenges of the HIV epidemic, adapt to changing contexts, and drive transformative change from within. **Partnerships and Collaboration:** Effective community empowerment relies on partnerships and collaboration between governments, civil society organizations, academia, and the private sector, leveraging collective strengths and resources to achieve common goals. Multi-sectoral partnerships facilitate knowledge exchange, resource sharing, and joint advocacy efforts, amplifying the impact of HIV prevention interventions and maximizing reach and coverage. By fostering collaboration across sectors, community empowerment initiatives create synergies, promote innovation, and build resilience, ultimately strengthening the collective response to the HIV epidemic in Africa.

Conclusion

From behavioral interventions to biomedical innovations, policy reforms to community empowerment efforts, Africa has demonstrated resilience, adaptability, and leadership in its response to the HIV/AIDS crisis. Innovations in behavioral interventions have fostered dialogue, dispelled myths, and promoted safer sexual practices, while biomedical breakthroughs such as PrEP, ART as prevention, and VMMC have provided effective tools for reducing HIV transmission and improving health outcomes. Structural reforms and policy innovations have created an enabling environment for HIV prevention, strengthening health systems, mobilizing resources, and promoting human rights and gender equality. Meanwhile, community empowerment and participation have empowered individuals to take ownership of their health, advocate for their rights, and drive positive change at the grassroots level.

References

1. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the Global Burden of Disease Study 2010. *Aids*. 2013;27(13):2003-2017.
2. Assefa Y, Gilks CF. Ending the epidemic of HIV/AIDS by 2030: Will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries? *International Journal of Infectious Diseases*. 2020; 100:273-277.
3. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
4. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
5. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
6. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.2196/links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf).
7. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
8. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004

9. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci.* 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
10. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
11. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
12. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-19.
13. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International.* 2020;32(22):101-119.
14. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation.* 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
15. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences.* 2015;4(4):911-916.
https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
16. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65.DOI: [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
17. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001)
18. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-119.
19. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-](https://doi.org/10.22192/ijcrms.2023.09.02.001)

[SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](#)

20. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](#).
21. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu Emmanuel Ifeanyi3 et al.IJC_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
22. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](#)
23. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
24. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
25. Obeagu EI, Ameorpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).
26. Obeagu EI, Scott GY, Ameorpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
27. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022;29-34.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
29. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-](#)

Citation: Obeagu EI. Empowering Progress: Impactful Innovations in HIV Prevention in Africa. Elite Journal of Public Health, 2024; 2 (3): 63-77

[based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](#).

30. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](#) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](#)
31. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](#) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](#).
32. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](#) https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf
33. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
34. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](#) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](#).
35. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
36. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
37. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Sтивен PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases.* 2022;10(4):1-7.

38. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
39. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):42-57.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
40. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
41. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
42. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjpr.in/links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
43. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
44. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.com/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
45. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
46. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
47. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci*. 2015;4(4):906-910.
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).

48. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
49. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
50. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
51. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.
52. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
53. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
54. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
55. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
56. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
57. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
58. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
59. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
60. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A

- review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
61. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
 62. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
 63. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
 64. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
 65. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
 66. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
 67. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
 68. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
 69. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
 70. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*. 2024;103(9):e37354.
 71. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
 72. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
 73. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
 74. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
 75. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>*;12(01).

76. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
77. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page*: <http://www.journalijar.com>;12(01).
78. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
79. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
80. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
81. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
82. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
83. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
84. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
85. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
86. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
87. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
88. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
89. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
90. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
91. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: <http://www.journalijar.com>;12(01).
92. McGillen JB, Stover J, Klein DJ, Xaba S, Ncube G, Mhangara M, Chipendo GN, Taramusi I, Beacroft L, Hallett TB, Odawo P. The emerging health impact of voluntary medical male circumcision in Zimbabwe: an evaluation using three epidemiological models. *PloS one*. 2018;13(7):e0199453.

93. Hankins CA, de Zaluondo BO. Combination prevention: a deeper understanding of effective HIV prevention. *Aids*. 2010;24: S70-80.
94. Lippman SA, Maman S, MacPhail C, Twine R, Peacock D, Kahn K, Pettifor A. Conceptualizing community mobilization for HIV prevention: implications for HIV prevention programming in the African context. *PloS one*. 2013;8(10): e78208.
95. Kerrigan D, Kennedy CE, Morgan-Thomas R, Reza-Paul S, Mwangi P, Win KT, McFall A, Fonner VA, Butler J. A community empowerment approach to the HIV response among sex workers: effectiveness, challenges, and considerations for implementation and scale-up. *The Lancet*. 2015;385(9963):172-85.
96. Delany-Moretlwe S, Cowan FM, Busza J, Bolton-Moore C, Kelley K, Fairlie L. Providing comprehensive health services for young key populations: needs, barriers and gaps. *Journal of the International AIDS Society*. 2015; 18:19833.